<DOC>
	<DOC>NCT00758680</DOC>
	<brief_summary>This study will asses the safety, tolerability, multiple-dose pharmacokinetics and pharmacodynamics of MK1006 in participants with type 2 diabetes.</brief_summary>
	<brief_title>A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)</brief_title>
	<detailed_description />
	<criteria>Participant has a BMI less than or equal to 42 kg/m^2 at the screening visit Participant has been diagnosed with Type 2 Diabetes that is being treated either by diet and exercise alone or by single or combination oral antihyperglycemic medications Participant is willing to follow a diet containing approximately 50% carbohydrates, 20% protein, and 30% fat during the study Participant is a nonsmoker and has not used nicotine containing products for ~ 6 months before start of study Participant must not be treated with three or more oral antihyperglycemic medications, insulin, or PPARgamma agonists Participant has a history of stroke, chronic seizures, or a major neurological disorder Participant has had an eye infection or other inflammatory eye condition within 2 weeks of first dose of study drug Participant has glaucoma or is blind Participant has a condition known to be related to cataract development Participant has had or will have incisional eye surgery within 6 months before screening or has had laser surgery (other than Lasik) within 3 months of screening Participant has a history of type 1 diabetes or ketoacidosis Participant cannot stop taking certain current medications during the study Participant consumes greater than 3 alcoholic beverages per day Participant consumes more than 6 servings of caffeinated beverages per day (1 serving is ~ 120 mg caffeine) Participant has a history of significant multiple or severe allergies or has had a reaction to or is intolerant of prescription/nonprescription drugs or food Participant uses recreational drugs or has had a history of drug abuse within 6 months of start of study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>